z-logo
open-access-imgOpen Access
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Author(s) -
Liu Cao,
Yingjun Li,
Sidi Yang,
Guanguan Li,
Qifan Zhou,
Jing Sun,
Tiefeng Xu,
Yang Yang,
Ruyan Liao,
Yongxia Shi,
Yujian Yang,
Tiaozhen Zhu,
SI-YAO HUANG,
Yanxi Ji,
Cong Feng,
Yinzhu Luo,
Yujun Zhu,
Hemi Luan,
Huan Zhang,
Jing-diao Chen,
Xue Liu,
Renru Luo,
Lihong Liu,
Ping Wang,
Yang Yu,
Fan Xing,
Bixia Ke,
Huanying Zheng,
Xiaoling Deng,
Wenyong Zhang,
Chuwen Lin,
Mǎng Shī,
Chunmei Li,
Yu Zhang,
Lu Zhang,
Jun Dai,
Hongzhou Lu,
Jincun Zhao,
Xumu Zhang,
Deyin Guo
Publication year - 2022
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.abm7621
Subject(s) - prodrug , bioavailability , pharmacology , medicine , oral administration , virus , drug , potency , adenosine , in vitro , virology , chemistry , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom